Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News H Lundbeck AS (PK) HLBAY

Alternate Symbol(s):  HLBBY

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment... see more

Current News (PINL:HLBAY)

Positive headline results from the Vyepti (eptinezumab-jjmr) RELIEF study

PR Newswire August 31, 2020

Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors

PR Newswire March 3, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc.

PR Newswire September 17, 2019

Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development

Business Wire March 20, 2019

Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder

Canada NewsWire February 22, 2019

TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)

PR Newswire May 2, 2018

Lundbeck Initiates Clinical Trial Evaluating Clobazam for Dravet Syndrome

Business Wire March 17, 2015

New Study: Art Therapy May Build Self-Esteem in People Living with Epilepsy

Business Wire December 8, 2014

Five-Year Data From SABRIL® (vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting

Business Wire December 8, 2014
View More News ››

Opinion & Analysis (PINL:HLBAY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:HLBAY)

Be the first to post on this bullboard.

Avrupa Minerals Ltd.

Avrupa Minerals Ltd.

Avrupa Minerals Ltd., a junior exploration and development company, engages in the acquisition and exploration of mineral ...
View More »

Podcasts